查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1447734

生殖器疱疹市场评估：按类型（诊断/治疗）、给药途径（口服、注射、局部）、最终用户（医院药房、零售药房、线上药房、其他）和地区划分的机会和预测（2017-2031）

Genital Herpes Market Assessment, By Type [Diagnosis, Treatment], Route of Administration [Oral, Injectable, Topical], End-user [Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others], Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 225 Pages | 商品交期: 3-5个工作天内

价格

全球生殖器疱疹市场规模将从2023年的22.5亿美元成长到2031年的33.9亿美元，2024-2031年预测期间复合年增长率为5.24%，预计规模也将持续成长。

全球生殖器疱疹市场受到多种因素的影响。 其中包括生殖器疱疹盛行率上升、认识提高、对局部药物的需求增加、单纯疱疹病毒诊断的创新、耐阿昔洛韦单纯疱疹病毒感染的发展以及对研究的更多关注。

生殖器疱疹盛行率上升是最重要的因素之一。 全世界有数百万人患有性传染病，而且这个数字还在持续上升。 因此，越来越需要有效的治疗方法和药物来控制症状并阻止传播。 对生殖器疱疹的认识不断提高是影响市场的另一个面向。 随着越来越多人意识到生殖器疱疹的危险和影响，对教育和预防措施的需求也随之增加。 新疗法和诊断设备研发的资金也在增加。

生殖器疱疹盛行率不断上升

由于生殖器疱疹盛行率不断增加，全球生殖器疱疹市场正以相当大的速度扩张。 患者数量的增加推动了治疗需求，并开发了药品、诊断和相关服务的新市场。 根据目前的基本估计，全球有超过5亿人患有生殖器疱疹。 疱疹的估计盛行率随着年龄的增长而增加，因为它是一种终生感染，而 HSV-2 的盛行率在世界卫生组织非洲区域 (AFRO) 和女性中较高。

提高意识

宣传活动的扩大也是推动市场的主要因素之一。 随着人们认识的提高，生殖器疱疹市场预计将稳步扩大，重点是预防、早期诊断和有效的管理技术。 随着大众对性传染病，特别是生殖器疱疹的了解不断增加，对教育、预防技术和治疗方案的需求也会增加。 政府机构和卫生组织的措施也有助于教育人们，提高他们对感染的了解，并激励他们尽快就医。

本报告调查了全球生殖器疱疹市场，提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素分析、案例研究、竞争格局、主要公司的简介等等。

目录

第1章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第4章全球生殖器疱疹市场展望

  • 市场规模/预测
  • 依类型
    • 诊断
    • 处理中
  • 依给药途径
    • 口头
    • 注射
    • 本地
  • 按最终用户
    • 医院药房
    • 零售药局
    • 网路药局
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 南美洲
    • 亚太地区
    • 中东/非洲
  • 各公司的市占率

第5章全球生殖器疱疹市场展望：依地区

  • 北美
  • 欧洲
  • 南美洲
  • 亚太地区
  • 中东/非洲

第 6 章市场映射

  • 依类型
  • 依给药途径
  • 按最终用户
  • 按地区

第7章宏观环境与产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 生长促进因素
  • 抑制生长的因素（问题/抑制因素）

第 9 章监理架构与创新

  • 临床试验
  • 专利情况
  • 监理机关的核准
  • 创新/新兴技术

第10章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（主要公司）
  • 专利分析（如果适用）

第11章价格分析

第 12 章案例研究

第13章主要公司展望

  • Bausch + Lomb Corporation
  • GlaxoSmithKline plc
  • Viatris Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories, Ltd.
  • Abbott Laboratories
  • Pfizer Inc.
  • Sun Pharmaceuticals Industries Ltd.
  • Fresenius SE & Co KGaA

第 14 章策略建议

第15章关于我们公司/免责声明

Product Code: MX11141

Global genital herpes market is projected to witness a CAGR of 5.24% during the forecast period, 2024-2031, growing from USD 2.25 billion in 2023 to USD 3.39 billion in 2031. The global genital herpes market is shaped by various factors. These include an increase in the prevalence of genital herpes, a rise in awareness, increasing demand for topical medications, innovations in HSV diagnosis, development of acyclovir-resistant HSV infections, and increased focus on research.

The rise in the prevalence of genital herpes is one of the most important factors. Millions of people are afflicted with STDs globally, and the number of cases is rising. Consequently, there is an increasing need for efficient therapies and drugs to control the signs and stop the spread. Growing awareness of genital herpes is another aspect influencing the global genital herpes market. The need for education and preventative measures is growing as more people are becoming aware of the dangers and repercussions of genital herpes. Funding for research and development of novel therapies and diagnostic instruments has increased.

The market for topical treatments for genital herpes is expanding due to the rising consumer demand propelling the growth of the global genital herpes market. Many patients choose topical therapies as they are simple to use and may be administered directly to the area that is affected. As a result, new topical drugs with reduced side effects and increased effectiveness have been developed. The global genital herpes market is being shaped by developments in HSV diagnosis. More rapid and accurate viral detection is possible with the development of new diagnostic techniques, which will enable early diagnosis and treatment.

The emergence of HSV infections resistant to acyclovir is another reason propelling the expansion of global genital herpes market. Novel and creative treatments are required to control the infection as the virus gets more resistant to conventional ones. Lastly, the market for genital herpes is expanding due to the greater emphasis on research. The likelihood of discovering novel treatments and cures increases with increased funds and resources allocated to research and development. These variables are influencing the global genital herpes market and propelling business expansion.

For instance, in September 2023, the U.S. National Institutes of Health laid out a strategic plan for Herpes Vaccine Research. The plan outlines a framework for HSV research with four strategic priorities, from expanding the understanding of the biology, pathophysiology, and epidemiology of HSV, quickening the pace of research to enhance HSV diagnosis, refining treatment approaches while pursuing a cure, and promoting research to prevent HSV infection.

Increase in the Prevalence of Genital Herpes

The global genital herpes market is expanding at a significant rate due to the increasing prevalence of genital herpes. The growing number of cases drives the treatment demand, which opens new markets for pharmaceuticals, diagnostics, and related services. Based on current estimates, over 500 million individuals globally suffer from genital herpes. The estimated prevalence of herpes rose with age as it is a lifetime infection and WHO African Region (AFRO) and women had a higher prevalence of HSV-2. Biologic vulnerability to HIV and HSV-2 is higher in women. Women in the WHO Africa Region are most likely to be exposed to HIV and have high HSV-2 prevalence, which increases their chance of contracting HIV and has detrimental effects on their health and well-being. Herpes symptoms can be more severe and frequent among those who have both HSV-2 and HIV, or who are coping with other illnesses that affect their immune systems.

Rise in Awareness

The expansion of awareness campaigns is one of the major factors driving the global genital herpes market. The market for genital herpes is anticipated to expand steadily as awareness grows and with a focus on prevention, early diagnosis, and efficient management techniques. The need for education, prevention techniques, and treatment choices increases as public knowledge of STDs, particularly genital herpes, rises. Due to increased awareness, appropriate behavior and a proactive attitude towards sexual health are encouraged, which propels the expansion of global genital herpes market. Governmental and healthcare organizations' initiatives help educate people and become more informed about infection and motivated them to seek medical attention as soon as possible.

The United Nations Fund for Population Activities (UNFPA) introduced "Just Ask!" in July 2023 as a chatbot to raise awareness of sexual and reproductive health and rights in India. It is a digital engagement platform powered by artificial intelligence (AI) designed to educate teenagers and young adults about their rights and sexual and reproductive health. Experts from UNFPA on sexual and reproductive health created the chatbot, which was released in close cooperation with the Madhya Pradesh government's Department of Public Health and Family Welfare and the National Health Mission (NHM).

Increasing Demand for Topical Medications

The growing demand for topical medications is increasing the market size of genital herpes globally. Herpes simplex virus infections of the skin, mucous membranes, and genitals are treated with topical medicine. Due to their advantages over oral treatments, topical therapies are becoming more and more popular in the global genital herpes market. Topical drugs are easier to apply than tablets or capsules since they are typically available in cream, gel, or ointment forms. Topical formulations are appealing to patients and healthcare professionals due to benefits such as convenience and ease of administration. Topical treatments can be applied directly to the lesion or affected area, offering faster relief and possibly fewer side effects than oral medications, which must first travel through the digestive system before reaching the infection site.

For instance, Zydus Lifesciences declared in March 2023 that has received the US Food and Drug Administration's (USFDA) final approval for Acyclovir Cream. Acyclovir is a member of the antiviral drug class. Acyclovir lotion is used to treat genital herpes.

Innovations in HSV Diagnosis

The global genital herpes market is undergoing a revolution due to the advancements in diagnosis techniques that are greatly improving patient results. The developments improve the effectiveness of diagnosis and the management and control of diseases, which in turn improves patient care and quality of life. Early diagnosis of HSV infections is now possible due to the development of faster and more reliable testing techniques, which lower the risk of transmission and enable timely treatment commencement. Innovative diagnostic technologies are boosting demand for genital herpes testing and treatment options, influencing the future landscape of the market by helping healthcare providers diagnose HSV infections more accurately.

The Truenat HSV 1/2 herpes test was introduced in January 2023 by Molbio Diagnostics. Approved by the Central Drug Standard Control Organisation (CDSCO), it is an RT-PCR test for herpes diagnosis that uses chips. There is no need for additional setup or equipment because the test is compatible with the current Truelab infrastructure.

Growing European Market

The global genital herpes market is growing significantly in Europe for several reasons. Large healthcare budgets are allotted in nations like Germany and the United Kingdom, allowing for investments in R&D and access to cutting-edge genital herpes therapies. Increased knowledge and understanding of genital herpes in these nations motivate people to seek prompt medical care, which fuels demand for genital herpes treatments and aids in the growth of the global genital herpes market. Furthermore, Europe's strict regulatory environment encourages market expansion. It is anticipated that the region will continue to grow steadily due to its favorable high level of awareness of cutting-edge STD treatment alternatives and patient demographics.

AiCuris, a German clinical-stage biopharmaceutical company, announced in July 2023 that it was concentrating on producing Pritelivir, a treatment for acyclovir-resistant herpes simplex virus infections, in phase 3 of development, to further strengthen its pipeline for infectious diseases.

Future Market Scenario (2024 - 2031F)

Social media and digital health platforms that educate young people about sexual and reproductive health are becoming more and more popular, which is contributing to the growth of the worldwide genital herpes market.

Robotic process automation is increasingly being used in the manufacturing of drugs used for treatment of genital herpes which will drive the global genital herpes market in the future.

AI-based digital diagnostic tools are increasingly being used for screening and diagnosing STIs driving the global genital herpes market.

The rise in the global genital herpes market will be fueled by changing lifestyles, as higher infection rates will lead to increased need for treatment.

Key Players Landscape and Outlook

Cooperation among academic institutions, healthcare providers, and other industry players is common in global genital herpes market. Small and medium-sized businesses are working together to make use of each other's experience, gain access to more resources, and broaden their reach in the market. These businesses have a competitive edge due to their capacity to introduce novel, efficient treatments to the market. Collaborations aid in the creation of novel antiviral medications, therapeutic vaccinations, and creative delivery methods, among other forms of new medical treatments. Patents and intellectual property rights give businesses protection and exclusivity for their creative treatment ideas, which makes them competitive.

A collaborative agreement to develop, produce, and market live vaccines against herpes simplex viruses (HSV-1 and HSV-2) in China was announced in October 2023 by Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (MH) and Rational Vaccines (RVx).

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Genital Herpes Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Type
    • 4.2.1.Diagnosis
    • 4.2.2.Treatment
      • 4.2.2.1.Acyclovir
      • 4.2.2.2.Famciclovir
      • 4.2.2.3.Valacyclovir
      • 4.2.2.4.Others
  • 4.3.By Route of Administration
    • 4.3.1.Oral
    • 4.3.2.Injectable
    • 4.3.3.Topical
  • 4.4.By End-user
    • 4.4.1.Hospital Pharmacies
    • 4.4.2.Retail Pharmacies
    • 4.4.3.Online Pharmacies
    • 4.4.4.Others
  • 4.5.By Region
    • 4.5.1.North America
    • 4.5.2.Europe
    • 4.5.3.Asia-Pacific
    • 4.5.4.South America
    • 4.5.5.Middle East and Africa
  • 4.6.By Company Market Share (%), 2023

5.Global Genital Herpes Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Type
      • 5.1.2.1.Diagnosis
      • 5.1.2.2.Treatment
      • 5.1.2.2.1.Acyclovir
      • 5.1.2.2.2.Famciclovir
      • 5.1.2.2.3.Valacyclovir
      • 5.1.2.2.4.Others
    • 5.1.3.By Route of Administration
      • 5.1.3.1.Oral
      • 5.1.3.2.Injectable
      • 5.1.3.3.Topical
    • 5.1.4.By End-user
      • 5.1.4.1.Hospital Pharmacies
      • 5.1.4.2.Retail Pharmacies
      • 5.1.4.3.Online Pharmacies
      • 5.1.4.4.Others
    • 5.1.5.United States*
      • 5.1.5.1.Market Size & Forecast
      • 5.1.5.1.1.By Value
      • 5.1.5.1.2.By Volume
      • 5.1.5.2.By Type
      • 5.1.5.2.1.Diagnosis
      • 5.1.5.2.2.Treatment
      • 5.1.5.2.2.1.Acyclovir
      • 5.1.5.2.2.2.Famciclovir
      • 5.1.5.2.2.3.Valacyclovir
      • 5.1.5.2.2.4.Others
      • 5.1.5.3.By Route of Administration
      • 5.1.5.3.1.Oral
      • 5.1.5.3.2.Injectable
      • 5.1.5.3.3.Topical
      • 5.1.5.4.By End-user
      • 5.1.5.4.1.Hospital Pharmacies
      • 5.1.5.4.2.Retail Pharmacies
      • 5.1.5.4.3.Online Pharmacies
      • 5.1.5.4.4.Others
    • 5.1.6.Canada
    • 5.1.7.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Type
  • 6.2.By Route of Administration
  • 6.3.By End-user
  • 6.4.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Regulatory Approvals
  • 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.Bausch + Lomb Corporation
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.GlaxoSmithKline plc
  • 13.3.Viatris Inc.
  • 13.4.Novartis AG
  • 13.5.Teva Pharmaceutical Industries Ltd.
  • 13.6.Dr. Reddy's Laboratories, Ltd.
  • 13.7.Abbott Laboratories
  • 13.8.Pfizer Inc.
  • 13.9.Sun Pharmaceuticals Industries Ltd.
  • 13.10.Fresenius SE & Co KGaA

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 2.Global Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 3.Global Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 4.Global Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 5.Global Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 6.Global Genital Herpes Market Share (%), By Region, 2017-2031F
  • Figure 7.North America Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 8.North America Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 9.North America Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 10.North America Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 11.North America Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 12.North America Genital Herpes Market Share (%), By Country, 2017-2031F
  • Figure 13.United States Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 14.United States Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 15.United States Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 16.United States Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 17.United States Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 18.Canada Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 19.Canada Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 20.Canada Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 21.Canada Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 22.Canada Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 23.Mexico Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 24.Mexico Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 25.Mexico Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 26.Mexico Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 27.Mexico Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 28.Europe Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 29.Europe Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 30.Europe Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 31.Europe Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 32.Europe Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 33.Europe Genital Herpes Market Share (%), By Country, 2017-2031F
  • Figure 34.Germany Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 35.Germany Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 36.Germany Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 37.Germany Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 38.Germany Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 39.France Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 40.France Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 41.France Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 42.France Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 43.France Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 44.Italy Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 45.Italy Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 46.Italy Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 47.Italy Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 48.Italy Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 49.United Kingdom Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 50.United Kingdom Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 51.United Kingdom Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 52.United Kingdom Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 53.United Kingdom Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 54.Russia Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 55.Russia Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 56.Russia Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 57.Russia Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 58.Russia Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 59.Netherlands Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 60.Netherlands Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 61.Netherlands Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 62.Netherlands Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 63.Netherlands Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 64.Spain Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 65.Spain Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 66.Spain Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 67.Spain Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 68.Spain Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 69.Turkey Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 70.Turkey Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 71.Turkey Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 72.Turkey Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 73.Turkey Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 74.Poland Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 75.Poland Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 76.Poland Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 77.Poland Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 78.Poland Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 79.South America Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 80.South America Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 81.South America Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 82.South America Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 83.South America Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 84.South America Genital Herpes Market Share (%), By Country, 2017-2031F
  • Figure 85.Brazil Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 86.Brazil Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 87.Brazil Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 88.Brazil Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 89.Brazil Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 90.Argentina Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 91.Argentina Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 92.Argentina Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 93.Argentina Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 94.Argentina Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 95.Asia-Pacific Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 96.Asia-Pacific Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 97.Asia-Pacific Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 98.Asia-Pacific Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99.Asia-Pacific Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 100.Asia-Pacific Genital Herpes Market Share (%), By Country, 2017-2031F
  • Figure 101.India Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 102.India Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 103.India Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 104.India Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 105.India Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 106.China Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 107.China Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 108.China Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 109.China Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 110.China Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 111.Japan Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 112.Japan Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 113.Japan Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 114.Japan Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 115.Japan Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 116.Australia Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 117.Australia Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 118.Australia Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 119.Australia Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 120.Australia Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 121.Vietnam Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 122.Vietnam Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 123.Vietnam Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 124.Vietnam Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 125.Vietnam Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 126.South Korea Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 127.South Korea Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 128.South Korea Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 129.South Korea Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 130.South Korea Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 131.Indonesia Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 132.Indonesia Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 133.Indonesia Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 134.Indonesia Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 135.Indonesia Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 136.Philippines Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 137.Philippines Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 138.Philippines Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 139.Philippines Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 140.Philippines Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 141.Middle East & Africa Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 142.Middle East & Africa Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 143.Middle East & Africa Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 144.Middle East & Africa Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 145.Middle East & Africa Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 146.Middle East & Africa Genital Herpes Market Share (%), By Country, 2017-2031F
  • Figure 147.Saudi Arabia Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 148.Saudi Arabia Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 149.Saudi Arabia Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 150.Saudi Arabia Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 151.Saudi Arabia Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 152.UAE Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 153.UAE Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 154.UAE Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 155.UAE Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 156.UAE Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 157.South Africa Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 158.South Africa Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 159.South Africa Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 160.South Africa Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 161.South Africa Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 162.By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163.By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023